Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system. (May 2022)

• Record Type: Journal Article
• Authors: Colman, Rebecca E.; Hagan, Christopher; Chiles, Peter; Seifert, Marva; Catanzaro, Donald G.; Kukhtin, Alexander V.; Norville, Ryan; Hauns, Laura; Bueno, Arial; Holmberg, Rebecca C.; Cooney, Christopher G.; Rodwell, Timothy C.
• Is Part Of: Journal of clinical tuberculosis and other mycobacterial diseases. Volume 27(2022)
• Publication Date: 2022-05
• Subjects: Multidrug-resistant tuberculosis diagnostic -- Benchtop automated system; Tuberculosis -- Periodicals; Mycobacterial diseases -- Periodicals; 616.995
• DOI: 10.1016/j.jctube.2022.100304
• Languages: English
• ISSNs: 2405-5794

Abstract

Abstract: While there has been progress in detection of drug resistant tuberculosis globally, WHO estimates only about half of the patients with bacteriologically confirmed tuberculosis were tested for rifampicin resistance over the past two years. To close this drug resistance diagnostic gap, an expansion of testing for rifampicin and isoniazid resistance is critically needed. The Akonni Biosystem Integrated System combines DNA extraction and a Lab-on-a-Film assembly (LFA) to perform rapid probe and PCR-based detection of resistance associated mutations to first-line anti-tuberculosis drugs. Using raw sputum samples from 25 tuberculosis patients at risk for drug resistance, we conducted a proof-of-concept study of the Integrated System with an MDR-TB assay. Performance of the Integrated System was compared to liquid Mycobacteria Growth Indicator Tube (MGIT) culture reference phenotypes using 2012 WHO endorsed critical concentrations for rifampicin and isoniazid. The overall percent agreement for rifampicin and isoniazid was 91.7% and 100% respectively, with agreement for rifampicin increasing to 95.7% after low-level resistance mutations in rpoB were excluded. The Integrated System, combining DNA extraction and LFA amplification, is a promising new tool for detection of both rifampicin and isoniazid using liquefied raw sputum.